EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis

Bernadett Farkas, Tamás Resál, Peter L Lakatos, Talat Bessissow, Jimmy K Limdi, Alessandro Armuzzi, Cristina Bezzio, Edoardo V Savarino, Simone Saibeni, George Michalopoulos, Mohamed Attauabi, Jakob Benedict Seidelin und 8 weitere

Clinical Gastroenterology and Hepatology · 2026-07 · 24 (7) · 1950-1959

DOI: 10.1016/j.cgh.2025.06.049 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-07. Verfasst von Bernadett Farkas und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gastroenterology, Department of Internal Medicine, University of Szeged, Szeged, Hungary; HCEMM-USZ Translational Colorectal Research Grou…. Hauptthemen laut MEDLINE: Pyrimidines, Colitis, Ulcerative, Piperidines, Heterocyclic Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Bolyai Foundation, H2020 European Institute of Innovation and Technology, Nemzeti Kutatási, Fejlesztési és Innovaciós Alap.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Comparative data on the effectiveness of tofacitinib (TOFA) and upadacitinib (UPA) in ulcerative colitis (UC) remain limited. We conducted a multicenter, retrospective cohort study to evaluate and compare the short- and mid-term effectiveness of TOFA and UPA in bio-experienced, moderate-to-severe UC. METHODS: Inverse probability weighting analysis was performed for demographics, baseline Mayo score, and baseline C-reactive protein [CRP] and fecal calprotectin [FCal], as well as concomitant corticosteroid use between the 2 treatment groups. The coprimary outcome was week 12 and 24 corticosteroid-free remission (CSFR) defined as clinical remission (CR) and CRP ≤5 mg/L, as well as not receiving steroids ≥30 days. We also assessed the rate of CR and biochemical remission (defined as CRP ≤5 mg/L and FCal ≤ 250 μg/g) during the first 6 months of therapy. RESULTS: A total of 350 patients with UC (246 TOFA, 104 UPA; mean age, 38.6 ±13.8 years; median follow-up, 11 months) were enrolled in the study. The likelihood of achieving CSFR at both week 12 (adjusted odds ratio [aOR], 2.2; 95% confidence interval [CI], 1.2-4.1) and week 24 (aOR, 2.2; 95% CI, 1.2-3.9) was found to be significantly higher in patients treated with UPA than in patients receiving TOFA. UPA was also associated with around 2-fold higher odds of reaching both CR (95% CI, 1.3-4.3; 95% CI, 1.0-3.4) and biochemical remission (95% CI, 1.3-4.4; 95% CI, 1.2-4.0) at the same timepoints compared with TOFA. No significant differences were seen in IBD-related hospitalization and early colectomy rates between the 2 treatment groups. No new safety signal was noted. CONCLUSIONS: UPA might be associated with better short- and mid-term clinical and biochemical outcomes compared with TOFA in refractory, moderate-to-severe UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesColitis, UlcerativePiperidinesHeterocyclic CompoundsHeterocyclic Compounds, 3-RingHumansFemaleRetrospective StudiesTreatment OutcomeMaleAdultMiddle Aged

Stichwörter der Autor:innen

IBDInflammatory Bowel DiseasesJAK InhibitorsTofacitinibUlcerative ColitisUpadacitinib

Substanzen

PyrimidinestofacitinibPiperidinesupadacitinibHeterocyclic CompoundsHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Center for Gastroenterology, Department of Internal Medicine, University of Szeged, Szeged, Hungary; HCEMM-USZ Translational Colorectal Research Group, Szeged, Hungary.
  • HCEMM-USZ Translational Colorectal Research Group, Szeged, Hungary.
  • Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada; Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
  • Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.
  • Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.
  • IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Förderung

  • Bolyai Foundation
  • H2020 European Institute of Innovation and Technology
  • Nemzeti Kutatási, Fejlesztési és Innovaciós Alap

Zitieren

APA

Farkas, B., Resál, T., Lakatos, P. L., Bessissow, T., Limdi, J. K., Armuzzi, A., Bezzio, C., Savarino, E. V., Saibeni, S., Michalopoulos, G., Attauabi, M., Seidelin, J. B., Fousekis, F. S., Katsanos, K., Bacsur, P., Bálint, A., Ivány, E., Szepes, Z., Farkas, K., & Molnár, T. (2026). Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 24(7), 1950-1959. https://doi.org/10.1016/j.cgh.2025.06.049

Vancouver

Farkas B, Resál T, Lakatos PL, Bessissow T, Limdi JK, Armuzzi A, et al. Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2026;24(7):1950-1959. doi:10.1016/j.cgh.2025.06.049

BibTeX
@article{Farkas2026,
  author = {Farkas, Bernadett and Resál, Tamás and Lakatos, Peter L and Bessissow, Talat and Limdi, Jimmy K and Armuzzi, Alessandro and Bezzio, Cristina and Savarino, Edoardo V and Saibeni, Simone and Michalopoulos, George and Attauabi, Mohamed and Seidelin, Jakob Benedict and Fousekis, Fotios S and Katsanos, Kostas and Bacsur, Péter and Bálint, Anita and Ivány, Emese and Szepes, Zoltán and Farkas, Klaudia and Molnár, Tamás},
  title = {Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {7},
  pages = {1950--1959},
  doi = {10.1016/j.cgh.2025.06.049}
}
Kostenlos starten →